Naftopidil

57149-07-2

392.49

H2O : < 0.1 mg/mL (insoluble); DMSO : 33.33 mg/mL (84.92 mM; Need ultrasonic)

GPCR/G Protein; Neuronal Signaling

Naftopidil (KT-611; BM-15275) is a selective alpha1-adrenoceptor antagonist, with antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia^[1]. IC50 & Target: alpha1-adrenoceptor^[1] In Vitro: Naftopidil suppresses human prostate tumor growth by altering interactions between tumor cells and stroma^[1].
Naftopidil (10 uM for PCa cells; 0.1-10 mym for PrSC) shows growth inhibitory effects on PrSC and PCa cells^[1].
Naftopidil (50 uM for E9 cells, 25 uM for PrSC; 48 hours) increased the level of cell-cycle regulatory protein p27 in E9 cells, but not PrSC^[1].
In Vivo: Naftopidil (10 mg/kg; p.o; daily, for 28 days) decreases microvessel density (MVD) in E9 + PrSC tumors mice model^[1].